Highlights
- •The prevalence of HFpEF in Japan is increasing, due primarily to population aging.
- •Phenotypical differences may exist between Japanese HFpEF and Western populations.
- •Characterization of Japanese HFpEF may provide new therapy specific to this cohort.
ABSTRACT
Heart failure (HF) with preserved ejection fraction (HFpEF) is a global health care
problem, with diagnostic difficulty, limited treatment options and high morbidity
and mortality rates. The prevalence of HFpEF is increasing because of the aging population
and the increasing burden of cardiac and metabolic comorbidities, such as systemic
hypertension, diabetes, chronic kidney disease, and obesity. The knowledge base is
derived primarily from the United States and Europe, and data from Asian countries,
including Japan, remain limited. Given that phenotypic differences may exist between
Japanese and Western patients with HFpEF, careful characterization may hold promise
to deliver new therapy specific to the Japanese population. In this review, we summarize
the current knowledge regarding the epidemiology, pathophysiology and diagnosis of
and the potential therapies for HFpEF in Japan.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Heart Disease and Stroke Statistics: 2021 Update: a report from the American Heart Association.Circulation. 2021; 143: e254-e743https://doi.org/10.1161/CIR.0000000000000950
- Evaluation and management of heart failure with preserved ejection fraction.Nat Rev Cardiol. 2020; 17: 559-573https://doi.org/10.1038/s41569-020-0363-2
- Heart failure with preserved ejection fraction: From mechanisms to therapies.Eur Heart J. 2018; 39: 2780-2792https://doi.org/10.1093/eurheartj/ehy301
- The world report on ageing and health: a policy framework for healthy ageing.Lancet. 2016; 387: 2145-2154https://doi.org/10.1016/S0140-6736(15)00516-4
- Government of Japan. Report on Aging Society. 2021; (n.d)
United Nations: Department of Economic and Social. World Population Ageing, 2019.
- CHART-2 Investigators. Trend of Westernization of etiology and clinical characteristics of heart failure patients in Japan: first report from the CHART-2 study.Circ J. 2011; 75: 823-833https://doi.org/10.1253/circj.cj-11-0135
- Impending epidemic: future projection of heart failure in Japan to the year 2055.Circ J. 2008; 72: 489-491https://doi.org/10.1253/circj.72.489
- Heart failure with preserved ejection fraction in Asia.Eur J Heart Fail. 2019; 21: 23-36https://doi.org/10.1002/ejhf.1227
- Forecasting the impact of heart failure in the United States.Circ Heart Fail. 2014; 6: 606-619https://doi.org/10.1161/HHF.0b013e318291329a
- Current status of cardiovascular medicine in the aging society of Japan.Circulation. 2018; 138: 965-967https://doi.org/10.1161/CIRCULATIONAHA.118.035858
- Prevalence and prognostic impact of cognitive frailty in elderly patients with heart failure: sub-analysis of FRAGILE-HF.ESC Heart Fail. 2022; 9: 1574-1583https://doi.org/10.1002/ehf2.13844
- Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF).Circ J. 2021; 85: 1438-1450https://doi.org/10.1253/circj.CJ-20-0947
- Impact of left ventricular chamber size on outcome in heart failure with preserved ejection fraction.Int Heart J. 2022; 63: 62-72https://doi.org/10.1536/ihj.21-486
- Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan: observations from the prospective, multicenter Kyoto Congestive Heart Failure (KCHF) registry.Circ J. 2018; 82: 2811-2819https://doi.org/10.1253/circj.CJ-17-1386
- Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD).Circ J. 2009; 73: 1893-1900https://doi.org/10.1253/circj.cj-09-0254
- Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.Eur J Heart Fail. 2017; 19: 1258-1269https://doi.org/10.1002/ejhf.807
- Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.ESC Heart Fail. 2019; 6: 475-486https://doi.org/10.1002/ehf2.12418
- Differences in blood pressure riser pattern in patients with acute heart failure with reduced mid-range and preserved ejection fraction.ESC Heart Fail. 2019; 6: 1057-1067https://doi.org/10.1002/ehf2.12500
- Different impact of changes in left ventricular ejection fraction between heart failure classifications in patients with acute decompensated heart failure.Circ J. 2019; 83: 584-594https://doi.org/10.1253/circj.CJ-18-0881
- Clinical significance of pulse pressure in patients with heart failure with preserved left ventricular ejection fraction.Eur J Heart Fail. 2016; 18: 1353-1361https://doi.org/10.1002/ejhf.559
- Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction.ESC Heart Fail. 2020; 7: 2752-2761https://doi.org/10.1002/ehf2.12867
- Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction.ESC Heart Fail. 2022; 9: 1853-1863https://doi.org/10.1002/ehf2.13885
- Efficacy of renin-angiotensin-aldosterone-system inhibitors for heart failure with preserved ejection fraction and left ventricular hypertrophy: from the KUNIUMI Registry Acute Cohort.J Cardiol. 2022; 79: 703-710https://doi.org/10.1016/j.jjcc.2021.12.002
- Association of obesity with heart failure outcomes in 11 Asian regions: a cohort study.PLos Med. 2019; 16e1002916
Ministry of Health, Labour and Welfare of Japan. National Health and Nutrition Survey Report 2019. n.d.
- Adiposity and incident heart failure and its subtypes.JACC Heart Fail. 2018; 6: 942https://doi.org/10.1016/j.jchf.2018.07.009
- Obesity-related heart failure with preserved ejection fraction.Heart Fail Clin. 2020; 16: 357-368https://doi.org/10.1016/j.hfc.2020.02.004
- Clinical phenogroups in heart failure with preserved ejection fraction.Heart Fail Clin. 2021; 17: 483-498https://doi.org/10.1016/j.hfc.2021.02.009
- Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction.Circulation. 2017; 136: 6-19https://doi.org/10.1161/CIRCULATIONAHA.116.026807
- Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study.Mayo Clin Proc. 2019; 94: 1199-1209https://doi.org/10.1016/j.mayocp.2018.11.037
- Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction.JACC Heart Fail. 2020; 8: 657-666https://doi.org/10.1016/j.jchf.2020.04.016
- Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction.Eur J Heart Fail. 2021; 23: 1648-1658https://doi.org/10.1002/ejhf.2254
- A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.J Am Coll Cardiol. 2013; 62: 263-271https://doi.org/10.1016/j.jacc.2013.02.092
- Metabolic inflammation in heart failure with preserved ejection fraction.Cardiovasc Res. 2021; 117: 423-434https://doi.org/10.1093/cvr/cvaa217
- Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.Eur Heart J. 2021; 42: 1595-1605https://doi.org/10.1093/eurheartj/ehaa823
- International comparison of abdominal fat distribution among four populations: The ERA-JUMP study.Metab Syndr Relat Disord. 2018; 16: 166-173https://doi.org/10.1089/met.2017.0132
- Pathophysiological role of fatty acid-binding protein 4 in Asian patients with heart failure and preserved ejection fraction.ESC Heart Fail. 2020; 7: 4256-4266https://doi.org/10.1002/ehf2.13071
- Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction.Eur J Nucl Med Mol Imaging. 2022; 49: 609-618https://doi.org/10.1007/s00259-021-05280-9
- Prevalence and clinical significance of diabetes in Asian versus white patients with heart failure.JACC Heart Fail. 2017; 5: 14-24https://doi.org/10.1016/j.jchf.2016.09.015
- High genetic risk scores for impaired insulin secretory capacity doubles the risk for type 2 diabetes in Asians and is exacerbated by Western-type diets.Diabetes Metab Res Rev. 2018; 34https://doi.org/10.1002/dmrr.2944
- Association of diabetes mellitus on cardiac remodeling, quality of life, and clinical outcomes in heart failure with reduced and preserved ejection fraction.J Am Heart Assoc. 2019; 8e013114https://doi.org/10.1161/JAHA.119.013114
- Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.J Am Coll Cardiol. 2014; 64: 541-549https://doi.org/10.1016/j.jacc.2014.05.030
- Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction.JACC Heart Fail. 2018; 6: 1-7https://doi.org/10.1016/j.jchf.2017.07.012
- Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes.Circulation. 2007; 116: I31-I37https://doi.org/10.1161/CIRCULATIONAHA.106.680157
- Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction.J Am Coll Cardiol. 2018; 72: 29-40https://doi.org/10.1016/j.jacc.2018.04.039
- Japanese nationwide PCI (J-PCI) Registry Annual Report 2019: patient demographics and in-hospital outcomes.Cardiovasc Interv Ther. 2022; 37: 243-247https://doi.org/10.1007/s12928-021-00832-0
- Chronic kidney disease and coronary artery disease: JACC state-of-the-art review.J Am Coll Cardiol. 2019; 74: 1823-1838https://doi.org/10.1016/j.jacc.2019.08.1017
- Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction.Eur J Heart Fail. 2020; 22: 2258-2268https://doi.org/10.1002/ejhf.1945
- Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction.J Cardiovasc Magn Reson. 2021; 23: 112https://doi.org/10.1186/s12968-021-00807-3
- Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE-HF cohort study.Eur J Heart Fail. 2020; 22: 2112-2119https://doi.org/10.1002/ejhf.1926
- Prognostic impact of Clinical Frailty Scale in patients with heart failure with preserved ejection fraction.ESC Heart Fail. 2021; 8: 3316-3326https://doi.org/10.1002/ehf2.13482
- Physical function, frailty, cognition, depression, and quality of life in hospitalized adults ≥60 years with acute decompensated heart failure with preserved versus reduced ejection fraction.Circ Heart Fail. 2018; 11e005254https://doi.org/10.1161/CIRCHEARTFAILURE.118.005254
- Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction.Circ Heart Fail. 2015; 8: 286-294https://doi.org/10.1161/CIRCHEARTFAILURE.114.001825
- Effect of acute high-intensity interval exercise on postexercise biventricular function in mild heart failure.J Appl Physiol. 2011; 110: 398-406https://doi.org/10.1152/japplphysiol.01114.2010
- Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study.Circulation. 2013; 128: 1085-1093https://doi.org/10.1161/CIRCULATIONAHA.113.001475
- High prevalence of occult heart failure with preserved ejection fraction among patients with atrial fibrillation and dyspnea.Circulation. 2018; 137: 534-535https://doi.org/10.1161/CIRCULATIONAHA.117.030093
- Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.Eur Heart J. 2019; 40: 689-698https://doi.org/10.1093/eurheartj/ehy809
- Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation.J Am Coll Cardiol. 2020; 76: 1051-1064https://doi.org/10.1016/j.jacc.2020.07.009
- Impact of right atrial remodeling in heart failure with preserved ejection fraction.J Card Fail. 2021; 27: 577-584https://doi.org/10.1016/j.cardfail.2020.12.016
- Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: A RELAX Trial ancillary study.Circ Heart Fail. 2014; 7: 123-130https://doi.org/10.1161/CIRCHEARTFAILURE.113.000568
- Right heart dysfunction in heart failure with preserved ejection fraction: the impact of atrial fibrillation.J Card Fail. 2018; 24: 177-185https://doi.org/10.1016/j.cardfail.2017.11.005
- Ethnic differences in atrial fibrillation among patients with heart failure in Asia.ESC Heart Fail. 2020; 7: 1419-1429https://doi.org/10.1002/ehf2.12696
- Prognostic importance of right ventricular-vascular uncoupling in acute decompensated heart failure with preserved ejection fraction.Circ Cardiovasc Imaging. 2020; 13e011430https://doi.org/10.1161/CIRCIMAGING.120.011430
- Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction.Eur J Heart Fail. 2020; 22: 489-498https://doi.org/10.1002/ejhf.1699
- Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction.Eur J Heart Fail. 2019; 21: 891-900https://doi.org/10.1002/ejhf.1464
- Incremental diagnostic value of la strain with leg lifts in heart failure with preserved ejection fraction.JACC Cardiovasc Imaging. 2013; 6: 749-758https://doi.org/10.1016/j.jcmg.2013.04.006
- Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study.Circulation. 2017; 135: 825-838https://doi.org/10.1161/CIRCULATIONAHA.116.024822
- The role of echocardiography in heart failure with preserved ejection fraction: what do we want from imaging?.Heart Fail Clin. 2019; 15: 241-256https://doi.org/10.1016/j.hfc.2018.12.004
- Echocardiography in the diagnostic evaluation and phenotyping of heart failure with preserved ejection fraction.J Cardiol. 2022; 79: 679-690https://doi.org/10.1016/j.jjcc.2021.11.003
- evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction.Circulation. 2018; 138: 861-870https://doi.org/10.1161/CIRCULATIONAHA.118.034646
- Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.Eur Heart J. 2018; 39: 2810-2821https://doi.org/10.1093/eurheartj/ehy268
- Salutary acute effects of exercise on central hemodynamics in heart failure with preserved ejection fraction.J Card Fail. 2021; 27: 1313-1320https://doi.org/10.1016/j.cardfail.2021.04.014
- How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).Eur Heart J. 2019; 40: 3297-3317https://doi.org/10.1093/eurheartj/ehz641
- Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community.JACC Heart Fail. 2020; 8: 640-653https://doi.org/10.1016/j.jchf.2020.03.013
- Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: a report from the Japanese multicenter registry.Int J Cardiol. 2021; 342: 43-48https://doi.org/10.1016/j.ijcard.2021.08.001
- Clinical usefulness of the HFA-PEFF diagnostic scoring system in identifying late elderly heart failure with preserved ejection fraction patients.Circ J. 2021; 85: 604-611https://doi.org/10.1253/circj.CJ-20-0784
- Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis.JACC Heart Fail. 2020; 8: 712-724https://doi.org/10.1016/j.jchf.2020.04.007
- Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Eur Heart J. 2015; 36: 2585-2594https://doi.org/10.1093/eurheartj/ehv338
- Estimating the global prevalence of transthyretin familial amyloid polyneuropathy.Muscle Nerve. 2018; 57: 829-837https://doi.org/10.1002/mus.26034
- Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study.Mod Pathol. 2011; 24: 1533-1544https://doi.org/10.1038/modpathol.2011.117
- Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm.ESC Heart Fail. 2021; 8: 2647-2659https://doi.org/10.1002/ehf2.13473
- Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.ESC Heart Fail. 2020; 7: 2829-2837https://doi.org/10.1002/ehf2.12884
- Natural history of wild-type transthyretin cardiac amyloidosis and risk stratificationusing a novel staging system.J Am Coll Cardiol. 2016; 68: 1014-1020https://doi.org/10.1016/j.jacc.2016.06.033
- Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study.Circulation. 2016; 133: 282-290https://doi.org/10.1161/CIRCULATIONAHA.115.018852
- Screening for transthyretin amyloid cardiomyopathy in everyday practice.JACC Heart Fail. 2019; 7: 709-716https://doi.org/10.1016/j.jchf.2019.04.010
- JCS/JHFS 2021 Guideline-focused update on diagnosis and treatment of acute and chronic heart failure.J Card Fail. 2021; 27: 1404-1444https://doi.org/10.1016/j.cardfail.2021.04.023
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2022; 145: e895-1032https://doi.org/10.1161/CIR.0000000000001063
- Empagliflozin in heart failure with a preserved ejection fraction.N Engl J Med. 2021; 385: 1451-1461https://doi.org/10.1056/NEJMoa2107038
- JCS 2017/JHFS 2017 Guideline on diagnosis and treatment of acute and chronic heart failure: digest version.Circ J. 2019; 83: 2084-2184https://doi.org/10.1253/circj.CJ-19-0342
- Improves the long-term prognosis in patients with congestive heart failure with preserved ejection fraction as well as in those with reduced ejection fraction.Int Heart J. 2016; 57: 600-606https://doi.org/10.1536/ihj.16-023
- Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial.Circulation. 2015; 131: 34-42https://doi.org/10.1161/CIRCULATIONAHA.114.013255
- Impact of readmissions on octogenarians with heart failure with preserved ejection fraction: PURSUIT-HFpEF registry.ESC Hear Fail. 2021; 8: 2120-2132https://doi.org/10.1002/ehf2.13293
- Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods.JACC Cardiovasc Imaging. 2020; 13: 245-257https://doi.org/10.1016/j.jcmg.2018.12.034
- Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial.JAMA. 2016; 315: 36-46https://doi.org/10.1001/jama.2015.17346
- Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction.N Engl J Med. 2019; 381: 1609-1620https://doi.org/10.1056/nejmoa1908655
- Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.Lancet. 2022; 399: 1130-1140https://doi.org/10.1016/S0140-6736(22)00016-2
- Phenotype-specific treatment of heart failure with preserved ejection fraction.Circulation. 2016; 134: 73-90https://doi.org/10.1161/CIRCULATIONAHA.116.021884
- Phenomapping for novel classification of heart failure with preserved ejection fraction.Circulation. 2015; 131: 269-279https://doi.org/10.1161/CIRCULATIONAHA.114.010637
- Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone.JACC Heart Fail. 2020; 8: 172-184https://doi.org/10.1016/j.jchf.2019.09.009
- Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.Eur J Heart Fail. 2020; 22: 1009-1018https://doi.org/10.1002/ejhf.1788
- Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis.JACC Heart Fail. 2019; 7: 678-687https://doi.org/10.1016/j.jchf.2019.04.019
- Effect of distinct lifestyle interventions on mobilization of fat storage pools: CENTRAL magnetic resonance imaging randomized controlled trial.Circulation. 2018; 137: 1143-1157https://doi.org/10.1161/CIRCULATIONAHA.117.030501
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.Diabetes Res Clin Pract. 2018; 142: 254-263https://doi.org/10.1016/j.diabres.2018.05.017
- The effect of dapagliflozin treatment on epicardial adipose tissue volume.Cardiovasc Diabetol. 2018; 17: 6https://doi.org/10.1186/s12933-017-0658-8
- Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue.Int J Cardiol. 2019; 274: 326-330https://doi.org/10.1016/j.ijcard.2018.06.106
- Prognostic impact of statin use in patients with heart failure and preserved ejection fraction.Circ J. 2015; 79: 574-582https://doi.org/10.1253/circj.CJ-14-0865
- Impact of weight loss in patients with heart failure with preserved ejection fraction: results from the FLAGSHIP study.ESC Heart Fail. 2021; 8: 5293-5303https://doi.org/10.1002/ehf2.13619
- Underweight is associated with poor prognosis in heart failure with preserved ejection fraction.Int Heart J. 2021; 62: 1042-1051https://doi.org/10.1536/ihj.21-195
- Geriatric nutritional risk index predicts all-cause deaths in heart failure with preserved ejection fraction.ESC Heart Fail. 2019; 6: 396-405https://doi.org/10.1002/ehf2.12405
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur Heart J. 2021; 42: 3599-3726https://doi.org/10.1093/eurheartj/ehab368
- Nationwide survey of multidisciplinary care and cardiac rehabilitation for patients with heart failure in Japan: an analysis of the AMED-CHF study.Circ J. 2019; 83: 1546-1552https://doi.org/10.1253/circj.CJ-19-0241
- Feasibility of home-based cardiac rehabilitation using an integrated telerehabilitation platform in elderly patients with heart failure: a pilot study.J Cardiol. 2021; 78: 66-71https://doi.org/10.1016/j.jjcc.2021.01.010
- Ablation versus drug therapy for atrial fibrillation in heart failure.Circulation. 2021; 143: 1377-1390https://doi.org/10.1161/CIRCULATIONAHA.120.050991
- Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation.J Cardiol. 2019; 74: 235-244https://doi.org/10.1016/j.jjcc.2019.02.014
- Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction.J Cardiovasc Electrophysiol. 2020; 31: 682-688https://doi.org/10.1111/jce.14369
- Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.J Am Coll Cardiol. 2013; 62: 1857-1865https://doi.org/10.1016/j.jacc.2013.07.020
- Clinical characteristics, management, and outcomes of japanese patients hospitalized for heart failure with preserved ejection fraction: a report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) registry.Circ J. 2018; 82: 1534-1545https://doi.org/10.1253/circj.CJ-18-0073
- Prognostic significance of the HFA-PEFF score in patients with heart failure with preserved ejection fraction.ESC Heart Fail. 2021; 8: 2154-2164https://doi.org/10.1002/ehf2.13302
- Cardiac power output is independently and incrementally associated with adverse outcomes in heart failure with preserved ejection fraction.Circ Cardiovasc Imaging. 2022; 15e013495https://doi.org/10.1161/CIRCIMAGING.121.013495
- Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.Int J Cardiol. 2018; 271: 132-139https://doi.org/10.1016/j.ijcard.2018.04.001
- Association between β-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry.J Card Fail. 2021; 27: 1165-1174https://doi.org/10.1016/j.cardfail.2021.04.015
- A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction: insights from the ESC-HFA EORP Heart Failure Long-Term Registry.Eur J Heart Fail. 2022; 24: 335-350https://doi.org/10.1002/ejhf.2408
- Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry.Neth Heart J. 2021; 29: 370-376https://doi.org/10.1007/s12471-020-01534-7
- Characterisation of the patients with suspected heart failure: experience from the SHEAF registry.Open Heart. 2021; 8e001448https://doi.org/10.1136/openhrt-2020-001448
- Long-term outcomes for heart failure patients with and without diabetes: from the Get With The Guidelines Heart Failure Registry.Am Heart J. 2019; 211: 1-10https://doi.org/10.1016/j.ahj.2019.01.006
- Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction a community-based study.Circ Heart Fail. 2012; 5: 710-719https://doi.org/10.1161/CIRCHEARTFAILURE.112.968594
- Relation of systolic blood pressure on the following day with post-discharge mortality in hospitalized heart failure patients with preserved ejection fraction.Int Heart J. 2019; 60: 876-885https://doi.org/10.1536/ihj.18-699
Article info
Publication history
Accepted:
September 13,
2022
Received in revised form:
September 13,
2022
Received:
June 15,
2022
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
